8 research outputs found
Aggressive Multifocal Form of Epithelioid Hemangioendothelioma ā Case Report
Epithelioid hemangioendothelioma (EHE) is a rare tumor of the vascular origin. It was first described in its pulmonary
form by Dail and Leibow in 1975. and named Ā»intravascular bronhioalveolar tumorĀ« (IVBAT). Since then, reports
of occurences of the tumor have been made for number of locations, but most often tumor can be found in soft tissues,
liver, lungs, bone and skin. It is considered to be a low or borderline malignant tumor with, usually, slow progression,
but aggressive forms have been descrided.We here report a case of a 46-year old female patient with multifocalmalignant
tumor spreading to lungs, liver, spleen and with synchronous involvement of lumbal vertebrae, illiac bones and central
nervous system dissemination. To the best of the authors knowledge, no case of malignant EHE with multiorgan involvement
of this proportions and synchronous central nervous system and bone involvement in one patient has been reported
to this date in English-speaking literature
Aggressive Multifocal Form of Epithelioid Hemangioendothelioma ā Case Report
Epithelioid hemangioendothelioma (EHE) is a rare tumor of the vascular origin. It was first described in its pulmonary
form by Dail and Leibow in 1975. and named Ā»intravascular bronhioalveolar tumorĀ« (IVBAT). Since then, reports
of occurences of the tumor have been made for number of locations, but most often tumor can be found in soft tissues,
liver, lungs, bone and skin. It is considered to be a low or borderline malignant tumor with, usually, slow progression,
but aggressive forms have been descrided.We here report a case of a 46-year old female patient with multifocalmalignant
tumor spreading to lungs, liver, spleen and with synchronous involvement of lumbal vertebrae, illiac bones and central
nervous system dissemination. To the best of the authors knowledge, no case of malignant EHE with multiorgan involvement
of this proportions and synchronous central nervous system and bone involvement in one patient has been reported
to this date in English-speaking literature
JAK2-V617F Mutation is Associated with Clinical and Laboratory Features of Myeloproliferative Neoplasms
The aim of this study is to investigate the differences of clinical and laboratory parameters between patients with JAK2-V617F positive myeloproliferative neoplasms (MPNs) and JAK2 wild type MPNs. DNA was isolated from peripheral blood granulocytes of 106 patients treated at Rijeka University Hospital Center: 41 with polycythemia vera (PV), 43 with essential thrombocythemia (ET), 9 with primary myelofibrosis (PMF) and 13 with myeloproliferative neoplasm-
-unclassifiable (MPN-u). The JAK2-V617F mutation was detected using allele specific PCR. Laboratory and clinical parameters were obtained from patientās medical records. The JAK2-V617F mutation was detected in 69% (73/106) patients with MPNs. The results revealed significantly different prevalence of JAK2-V617F mutation, between MPNs entities: 88% in PV, 58% in ET, 56% in PMF and 54% in MPNs-unclassified disorders. The JAK2-V617F mutation significantly
correlated with higher leukocyte count and alkaline phosphatase score in ET group and with higher platelets count, leukocyte
alkaline phosphatase score and serum lactate dehydrogenase in PV group. Vascular events were associated with elevated platelets count in wholeMPNs group, with higher platelets and leukocyte count in ET and with splenomegaly in PV patients. Clinical and laboratory data revealed significant contribution of JAK2-V617F mutation to the development of clinical phenotype in patients with distinct subgroups of MPNs
Association of pre-treatment bone marrow morphology and achievement of BCR-ABL1 transcript milestones in CML
Chronic myeloid leukemia (CML) is characterized by the fusion gene BCR-ABL1 which encodes aberrantly functioning tyrosine kinase. Treatment with tyrosine kinase inhibitors (TKI) is a landmark of CML management and the main goal is to achieve major molecular response (MMR) which is defined as BCR-ABL1IS ā¤ 0.1 % at 12 months of therapy. The aim of this study is to analyze histologic features of bone marrow (BM) in CML patients at the time of diagnosis and compare it to the level of BCR-ABL1IS transcript at 3 (BCR-ABL1IS ā¤10 % early molecular response; EMR) and 12 months (MMR) as well as to so called molecularly undetectable leukemia (MUL) to see weather bone marrow morphology can be of value in predicting achievement molecular response milestones. Thirty-two bone marrow biopsies of CML patients, prior TKI therapy, were re-evaluated and CD34 immunohistochemistry was performed to examine microvessel density (MVD) and microvessel area (MVA) and subsequently compared it to the level of BCR-ABL1IS transcript. This study showed statistically significant association between BM hypercellularity and EMR (p = 0.048) and MUL (p = 0.034), peri-trabecular adipocyte distribution and EMR and MUL (p = 0.027 and p = 0.011, respectively), MMR and bone marrow fibrosis (p = 0.029), loose megakaryocyte clustering and EMR and MUL (p = 0.004 and p = 0.018, respectively), absence of naked nuclei and MUL (p = 0.033) but there was no statistically significant association with vascular parameters. These results suggest that some bone marrow morphologic features prior TKI therapy might be indicators of favorable molecular response
JAK2-V617F Mutation is Associated with Clinical and Laboratory Features of Myeloproliferative Neoplasms
The aim of this study is to investigate the differences of clinical and laboratory parameters between patients with JAK2-V617F positive myeloproliferative neoplasms (MPNs) and JAK2 wild type MPNs. DNA was isolated from peripheral blood granulocytes of 106 patients treated at Rijeka University Hospital Center: 41 with polycythemia vera (PV), 43 with essential thrombocythemia (ET), 9 with primary myelofibrosis (PMF) and 13 with myeloproliferative neoplasm-
-unclassifiable (MPN-u). The JAK2-V617F mutation was detected using allele specific PCR. Laboratory and clinical parameters were obtained from patientās medical records. The JAK2-V617F mutation was detected in 69% (73/106) patients with MPNs. The results revealed significantly different prevalence of JAK2-V617F mutation, between MPNs entities: 88% in PV, 58% in ET, 56% in PMF and 54% in MPNs-unclassified disorders. The JAK2-V617F mutation significantly
correlated with higher leukocyte count and alkaline phosphatase score in ET group and with higher platelets count, leukocyte
alkaline phosphatase score and serum lactate dehydrogenase in PV group. Vascular events were associated with elevated platelets count in wholeMPNs group, with higher platelets and leukocyte count in ET and with splenomegaly in PV patients. Clinical and laboratory data revealed significant contribution of JAK2-V617F mutation to the development of clinical phenotype in patients with distinct subgroups of MPNs